Results 201 to 210 of about 117,026 (248)

Clinical applications of somatostatin analogs

Trends in Endocrinology & Metabolism, 1990
The somatostatin analog Sandostatin is successfully used in the treatment of metastatic endocrine pancreatic tumors, carcinoids, and acromegaly. In addition, somatostatin receptors are also present on other tumors in man, therefore making it possible to demonstrate these tumors by the administration of (123)I-coupled to a somatostatin analog.
S W, Lamberts, E P, Krenning, J G, Klijn, J C, Reubi   +3 more
openaire   +2 more sources

Octreotide: A Synthetic Analog of Somatostatin

Drug Intelligence & Clinical Pharmacy, 1988
Octreotide is an investigational synthetic peptide exhibiting actions similar to those of endogenous somatostatin. It has a longer half-life than the native hormone and can be administered by subcutaneous injection. Octreotide inhibits the secretion of growth hormone and numerous regulatory peptides of the gastroenteropancreatic system.
openaire   +2 more sources

Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

Current Molecular Medicine, 2013
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M, ARVIGO, MARICA, Steffani L, FERONE, DIEGO, Magni P.   +4 more
openaire   +4 more sources

Somatostatin: Analogs with Selected Biological Activities

Science, 1976
[D-Cys 14 ]-Somatostatin is the first analog of somatostatin found to be more potent in inhibiting glucagon and growth hormone secretion than it is in inhibiting insulin secretion. [D-Trp 8 ]-Somatostatin is eight to ten times more potent than somatostatin in inhibiting insulin, glucagon, and
M, Brown, J, Rivier, W, Vale
openaire   +3 more sources

The Role of Somatostatin Analogs in Cushing's Disease

Pituitary, 2004
Somatostatin (SRIF) has been proposed to be of therapeutic interest in the medical treatment of Cushing's disease. While in vitro data demonstrate the presence of SRIF-receptor subtype (sst) expression in corticotroph adenomas, the current clinically available SRIF-analog Octreotide, predominantly targeting sst(2), is ineffective in lowering ACTH ...
van der Hoek, Joost, Lamberts, S.W.J., Hofland, Leo   +2 more
openaire   +3 more sources

[Somatostatin analogs in oncology].

Bulletin du cancer, 1991
Somatostatin octapeptide analogues have a longer half-life and are more potent than natural somatostatin (SS-14). Somatostatin analogues are presently approved for the treatment of gastrointestinal (GI) endocrine cancers such as carcinoids, vipomas and glucagonomas.
F, Thomas, H, Parmar, G, Prevost, J M, Kuhn, J L, Bejot, J P, Moreau, A, Bogden   +6 more
openaire   +1 more source

People also looked at

Frontiers in Endocrinology, 2021
David Taïeb, Abhishek Jha
exaly  

Somatostatin: The Search for Analogs

Science, 1975
openaire   +2 more sources

[Somatostatin, somatostatin analogs and their clinical use].

Casopis lekaru ceskych, 2003
Somatostatin is a hormone with broad spectrum of physiological effects. Somatostatin and its analogues are employed in the diagnosis and treatment of various clinical conditions. The article reviews the use of somatostatine and somatostatine analogues in the clinical medicine.
openaire   +1 more source

Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis

Journal of Clinical Endocrinology and Metabolism, 2007
Philippe Chanson, Andrea Giustina, Patrick Maison   +2 more
exaly